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Germline and somatic mutations in RAS and its downstream effectors are found in several congenital conditions
affecting the skin. Here we demonstrate that activation of BRAF in the embryonic mouse ectoderm triggers both
craniofacial and skin defects, including hyperproliferation, loss of spinous and granular keratinocyte differentia-
tion, and cleft palate. RNA sequencing of the epidermis confirmed these findings but unexpectedly revealed
evidence of continued epidermal maturation, expression of 480% of epidermal differentiation complex genes,
and formation of a hydrophobic barrier. Spinous and granular differentiation were restored by pharmacologic
inhibition of MAPK/ERK kinase or BRAF. However, restoration of epidermal differentiation was non-cell
autonomous and required dermal tissue to be present in tissue recombination studies. These studies indicate
that early activation of the RAF signaling pathway in the ectoderm has effects on specific steps of epidermal
differentiation, which may be amenable to treatment with currently available pharmacologic inhibitors.
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INTRODUCTION
In addition to its well-known involvement in cancer, muta-
tions in the RAS pathway can also be found as germline or
early somatic mosaic mutations (Hafner and Groesser, 2013;
Rauen, 2013). These early mutations occur in a spectrum of
congenital diseases, which affect internal organ, skin and hair
development, several types of neoplasms, and constitutional
maturation. Understanding the pathogenesis and timing of
these defects is critical to implementing the use of widely
available RAS pathway inhibitors in the treatment of these
children early in the course of disease.
The genetics of RAS/MAPK (mitogen-activated protein
kinase)-associated diseases suggest that mutations trigger
RAS paralog and effector-specific developmental and patho-
logic responses. HRAS mutations are far more common in the
Costello syndrome than are KRAS mutations (95% HRAS; 5%
KRAS; 0% NRAS) (Aoki et al., 2008). Mutations in BRAF and
RAF1 are exclusively involved in the cardiofaciocutaneous
syndrome (Rodriguez-Viciana et al., 2006) and the Noonan
syndrome (Razzaque et al., 2007), respectively. Germline
mutations in parallel RAS effector pathways, AKT/ PTEN,
cause yet other distinct diseases (Liaw et al., 1997; Pilarski
et al., 2013). Finally, early post-zygotic mutations also
disproportionately involve specific RAS paralogs (HRAS,
KRAS) and RAS effectors (AKT1) in diseases such as
epidermal nevus, nevus sebaceous, Schimmelpennig, and
Proteus syndromes (Lindhurst et al., 2011; Groesser et al.,
2012; Levinsohn et al., 2013).
The spectrum of skin disease in RAS/MAPK syndromes
suggests that the ectoderm discriminates between mutations
in specific effectors and paralogs. In the HRAS-associated
Costello syndrome, children develop redundant skin folds
and papillomas, whereas BRAF/MEK (MAPK/ERK kinase)-
associated disease is associated with flaky skin (ichthyosis),
perifollicular hyperkeratosis (keratosis pilaris), and lacks papil-
lomas (Turnpenny et al., 1992; Siegel et al., 2011). RAF1
mutations in the Noonan syndrome children trigger neither of
the above cutaneous features (Roberts et al., 2006). The
mechanisms that are responsible for differences in cutaneous
responses to paralogs and downstream effectors of RAS are not
known.
To study the effects of congenital BRAF activation of
epidermal development, we used a knock-in model to activate
BRAF (BrafV600E) in the ectoderm during embryogenesis.
BRAF activation induces hyperplasia and interferes with
progressive differentiation of the embryonic epidermis, where
intermediate steps in differentiation are lost. Through RNA
sequencing, in situ hybridization and skin barrier assay,
we find that maturation of the epidermis and barrier formation
continues. Inhibitors of either MEK or BRAF rescue spinous
and granular keratinocyte differentiation in explants of K14-
cre; BrafV600E mice, demonstrating both plasticity and con-
tinued responsiveness of affected epidermis. These findings
reveal that congenital activation of BRAF causes specific cell
identity defects in epidermal development and provides
insights into the mechanisms and application of BRAF/MEK
inhibition in the treatment of skin disease.
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RESULTS
Congenital activation of BRAF in the embryonic ectoderm
To activate BRAF in the ectoderm, we utilized a mouse model,
where expression of a mutant allele (BrafV600E) remains under
the control of its endogenous locus and produces mutant
product following Cre-mediated deletion of a transcription
stop cassette (Dankort et al., 2007). BrafV600E floxed females
were bred to Keratin 14 (K14)-cre) transgenic males, which
express Cre in the epidermis at embryonic day (E) 14.5
(Vasioukhin et al., 1999). K14-cre-positive, BrafV600E-positive
(K14-cre; BrafV600E) offspring were produced at near expected
Mendelian frequency when assessed prior to birth (25.6%
observed; 25% expected from 167 late stage embryos).
Postnatally, the majority of K14-cre; BrafV600E newborns
were cannibalized by adults, and only three K14-cre;
BrafV600E mice out of 420 litters were detected at the time
of weaning. In litters observed at the moment of birth, K14-
cre; BrafV600E newborns showed severe ectodermal defects,
including thick, fissured scale overlying translucent edematous
skin, and displayed rhythmic ventilation and pink oxyge-
nation. Further examination of K14-cre; BrafV600E newborns
also revealed lack of ingested milk in their stomachs and cleft
palate defects in 484% (Figure 1b). The latter defect may
result from Cre expression in the palate epithelium of K14-cre
animals (Okubo et al., 2009). Histologic analysis of the skin
revealed a thickened epidermis, basaloid cells, cytolysis, and
loss of keratohyalin granules (Figure 1c). Although a stratified
epithelium was present in K14-cre; BrafV600E mice, immuno-
fluorescent analysis revealed loss of K10-positive spinous and
loricrin/filaggrin (LOR/FLG)-positive granular keratinocytes
(Figure 1c). The K14-cre; BrafV600E epidermis was hyperproli-
ferative as evidenced by increased BrdU-staining and the
overexpression of K6 protein.
Congenital BRAF activation does not prevent continued
differentiation
To characterize the differentiation and fate of the K14-cre;
BrafV600E epidermis, high-throughput sequencing of transcripts
was performed from the E17.5 epidermis, when the skin was
phenotypically abnormal but lacked extensive signs of cyto-
lysis seen at later stages. Pooled total RNA from four control
littermate and mutant E17.5 epidermis was used to generate
48.4 and 56.3 million read libraries, respectively, and unique
reads were aligned to the genome and annotated (Figure 2). A
total of 2,189 coding genes were differentially expressed in the
K14-cre; BrafV600E epidermis, many of which participate in
epidermal differentiation and keratinization (Figure 2a).
Because of the heterogeneity of epidermal tissue, gene
expression data may also reflect the presence of other cell
types and follicular tissues. These data were used to study the
activity of genes representing specific epidermal lineages
(Figure 2b; Supplementary Figure S1 online), including late
steps in differentiation, which involve activation of 470
epidermal differentiation complex genes (de Guzman Strong
et al., 2010). Read coverage within the 3.3 Mb interval of
conserved gene cluster was analyzed and identified 63 trans-
criptional units, which are located in five physical groups
(Figure 2c). Loss of gene expression was most prominent in
the LCE-like group III, where the majority of these genes were
decreased by twofold except for four outliers in this group
representing Lce3 paralogs, which were upregulated
(Figure 2d). In the remaining epidermal differentiation com-
plex groups, 485% (41 genes) were expressed at normal or
higher levels in K14-cre; BrafV600E epidermis (Supplementary
Figure S2 online). These findings reveal that despite the loss of
early and intermediate gene differentiation, the vast majority
of transcriptional features of late differentiation remain active.
To confirm transcriptional changes identified by RNA-seq of
pooled samples, real-time quantitative PCR for select differ-
entiation markers was performed on individual embryos
(Figure 3 and Supplementary Table S1 online). K14-cre;
BrafV600E consistently demonstrated high levels of basal line-
age gene expression (K5, K14), whereas spinous (K1, K10) and
granular (Lor, Flg)-specific gene expression was markedly
reduced (Figure 3b). Late epidermal differentiation genes,
Lce3b, Lce3c, S100a1, S100a10, and Sprr2i, were still
expressed in the K14-cre; BrafV600E embryos and in some
cases at higher levels than in wild-type littermates.
To identify the pattern of differentiation in K14-cre;
BrafV600E epidermis, RNA in situ hybridization was performed
(Figure 3c). The patterns of early, intermediate, and late
terminal differentiation gene expression in wild type and
K14-cre; BrafV600E embryos demonstrated that late terminal
differentiation gene expression remains restricted to the most
distal layers. Localization of gene expression was further
confirmed by tyramide-based detection, which produces a
nondiffusible signal (Supplementary Figure S3 online). Thus, a
spatial or temporal mechanism persists in the K14-cre;
BrafV600E epidermis allowing for layer-specific gene expression
in the upper epidermis.
Terminal steps in epidermal differentiation are critical for
generating a hydrophobic barrier. This barrier becomes
evident between E16.5 and E17.5 and can be detected by
exclusion of water-soluble dyes, such as toludidine blue
(Hardman et al., 1998). Between E14.5 and E17.5
(Supplementary Figure S4 online.), K14-cre; BrafV600E embryos
appeared opaque relative to littermates at E16.5 and showed
widespread hyperkeratosis at E17.5 (Supplementary Figure S4a
online). Cornified sheets from K14-cre; BrafV600E embryos at
E18.5 were more brittle compared to wild-type littermates
(Supplementary Figure S4b online). At E16.5, partial dye
exclusion was visible in wild-type littermates (light blue) in
the dorsal skin (Supplementary Figure S4b online). A similar
dorsal pattern of dye exclusion was present in K14-cre;
BrafV600E embryos, but dye exclusion was more complete
resulting in its white appearance. By E17.5 and just prior to
birth, wild type and K14-cre; BrafV600E embryos demonstrated
similar patterns of barrier dye staining. Thus, in the presence of
BrafV600E, the epidermis is still capable of producing a
hydrophobic barrier.
Plasticity and requirements for layer identity in response to
BRAF and MEK inhibition
Pharmacologic inhibition of c-RAF, BRAF, and MEK1/2 is a
major focus in cancer drug discovery and may be a source for
potential therapies in rare childhood disorders. To explore this
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possibility, mouse embryonic explants containing E17.5-E18.5
skin biopsies were cultured for 24 hours in the presence of
inhibitors of BRAF or MEK1/2 (Figure 4). PLX4720 is selective
inhibitor of BRAF with a 10-fold higher affinity for BRAFV600E
than for wild-type BRAF (Tsai et al., 2008; Bollag et al., 2010).
Paradoxically, low doses of PLX4720 (o1mM) lead to
compensatory activation of c-RAF and MEK1/2 and proli-
feration, resulting in increased keratoacanthomas and
squamous cell carcinomas (Chapman et al., 2011). As a
result, high doses (410mM) of PLX4720 and other BRAF
inhibitors are used to suppress RAF paralogs and MEK
(Poulikakos et al., 2010).
To assess BRAF inhibition in small amounts of explanted
tissues, we assessed expression of a downstream target gene,
Dusp6, which is induced by RAS/MAPK signaling. Dusp6 was
elevated in K14-cre; BrafV600E epidermis and downregulated
in the presence of high-dose (450mM) PLX4720 (Figure 4a,
left panel) (Bloethner et al., 2005). We next assessed early
differentiation in response to BRAF inhibition (Figure 4a, right
panel) and found increased K1, K10, and Lor expression in
K14-cre; BrafV600E epidermis (P¼0.006) and in wild-type
littermate epidermis.
To confirm that inhibition of BRAF and downstream
effectors, MEK1/2, are responsible for the reversal of the
K14-cre; BrafV600E phenotype, we also treated explants with
U0126, which is a noncompetitive inhibitor of MEK1 and
MEK2 (Sebolt-Leopold, 2008). MEK inhibition resulted in
decreased Dusp6 (Mukhopadhyay et al., 2012), and
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Figure 1. Phenotype of K14-cre; BrafV600E neonatal and perinatal mice. (a) Appearance of normal neonatal (upper row) and K14-cre; BrafV600E (bottom row)
littermates. The K14-cre; BrafV600E skin appeared flaky and fissured overlying areas of translucent skin. (b) Cleft palate defects in K14-cre; BrafV600E whole mount
preparations were counterstained with toluidine blue. (c) Histologic and immunofluorescent analysis of K14-cre; BrafV600E (BrafV600E) neonatal skin. Hematoxylin
and eosin (HE)-stained sections demonstrate thickened epidermis, separation of individual cells, and severe reduction in cytoplasmic keratohyalin granules.
Immunofluorescent staining for K10, BrdU, loricrin (LOR), filaggrin (FLG), and K6 is shown for perinatal wild-type littermate and K14-cre; BrafV600E E18.5-P0
mouse skin. Note the absence of K10-positive-spinous keratinocytes and LOR/FLG-positive granular keratinocytes in the K14-cre; BrafV600E mouse skin. K6, a
marker for hyperproliferative skin, is increased in the K14-cre; BrafV600E mouse skin. Scale bars=20mm.
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Figure 2. RNA sequencing identifies the fate of epidermis in BrafV600E mutant mice and persistence of EDC gene expression. (a) Functional classification of genes
differentially expressed in E17.5 K14-cre; BrafV600E epidermis demonstrating number of genes and statistical significance of their association. (b) Read coverage of
wild type vs. K14-cre; BrafV600E transcripts across the mouse Krt14 and Krt10 loci. (c) Intermediate and late differentiation genes clustered in the EDC locus and
close proximity of closely related paralogs. (d) Volcano plots of relative expression of all EDC group genes from pooled wild type vs. K14-cre; BrafV600E embryos.
Specific groups of EDC genes, LCE-like (green), SPRR-like (red), and S100 family genes (blue), are colored and shown as balloons in respective cluster III, IV, and V.
The levels of gene expression in RNA-seq are estimated from (b) and have associated log2 q-values or false discovery rates (vertical axis) for this estimate. Note: this
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Figure 3. Expression of intermediate and late stage epidermal differentiation genes in K14-cre; BrafV600E mice. (a) Differentiation markers used to identify basal
(SB), spinous (SS), granular (SG), and cornified envelope (SC) keratinocytes. (b) Real-time PCR for gene expression at E17.5 skin reveals loss of spinous and granular
differentiation markers in K14-cre; BrafV600E embryos and the presence of late differentiation markers (Lce3b, Lce3c, Sprr2i, S100a1, and S100a10). Error bars
represent SD of four animals of each genotype. (c) E17.5 in situ hybridization of basal K5/K14, spinous K1/K10, granular Lor/Flg, involucrin, and cornified envelope
Lce3b keratinocyte gene expression. These studies show the loss of spinous and granular keratinocyte gene expression and pattern of involucrin and cornified
envelope genes in upper layers. Supplementary Figure S3 online further localizes gene expression by tyramide signal amplification. Scale bars=20mm.
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reactivation of spinous and granular layer gene expression (K1,
K10, Lor) (Figure 4b) and partial correction of other genes
(Supplementary Figure S7 online). These studies indicated that
continuous BRAF activity via MEK activation is necessary for
skin defects and that plasticity remains in the K14-cre;
BrafV600E mice. To identify which layers of the epidermis
respond to BRAF/MEK inhibition, we performed immunofluor-
escent and in situ hybridization studies on PLX4720-treated
explants (Figure 4 and not shown). PLX4720 and U0126
restored K10-positive staining of cells in layer number 2
through 4 of K14-cre; BrafV600E explants but did not activate
K10 in more distal layers. In contrast, the distal layers of the
wild-type epidermis express both K10 and granular layer
proteins––e.g., LOR. In K14-cre; BrafV600E mice, this distal
layer is, however, able to respond to BRAF or MEK inhibition
in its expression of LOR (Figure 4).
Plasticity in the above studies could arise from basal
keratinocytes responding to BRAF inhibition or keratinocytes
already residing in distal layers. To label these populations, we
performed a pulse-chase labeling to follow the fate of
proliferating basal keratinocytes after BRAF inhibition
(Figure 5 and Supplementary Figure S8 online). BrdU was
introduced in utero to pregnant females, and embryos and skin
explants were isolated 2 hours later to identify pulse-labeled
cells. In K14-cre; BrafV600E explants, 47.3±4.4% of basal
keratinocytes vs. 29.8±4.7% in wild-type basal keratinocytes
were BrdU-labeled at t¼ 2 hours (Figure 5a). After a 24-hour
chase in BrdU-free culture, we found that the majority of K10-
and LOR-positive keratinocytes in PLX4720-treated explants
do not arise from label-retaining keratinocytes cells. These
observations suggest that PLX4720 inhibition triggers K10 and
Lor gene expression in post-mitotic layers.
Non-cell autonomous requirements of BrafV600E explants
The persistence of spatial patterning in K14-cre; BrafV600E
epidermis suggested that spinous and granular cell identities
may still be silently present in the epidermis, despite their
lack of layer-specific gene expression. To test for the con-
tinued presence of ‘‘silent’’ spinous and granular layer
identity, we studied whether the keratinocyte response to
BRAF inhibition was cell-autonomous. Using dissociated
keratinocytes from K14-cre; BrafV600E embryos, cells were
treated with BRAF inhibitor for 24 hours and tested for K10
and LOR reactivation (Supplementary Figure. S5 online).
Under these conditions, neither K10 nor LOR expression
was reactivated even though cells remain transcriptionally
active. These observations suggest that reemergence of
spinous and granular layer identity in the K14-cre; BrafV600E
epidermis is not a cell-autonomous process.
Because reactivation of spinous and granular keratin-
ocyte identities failed to occur in dissociated cells, we
further tested whether surrounding tissues contribute
to the epidermal response to BRAF inhibition. Previous
tissue recombination studies suggest an important role for
the dermis in the histogenesis of the epidermis (Sengel,
1976). Therefore, we removed the dermis and tested the
response of epidermal sheets from wild type and
K14-cre; BrafV600E mouse embryos to PLX4720 (Figure 6).
In the absence of the dermis, neither K10 nor LOR
expression was restored by PLX4720 (Figure 6a and b). As
a control, we also tested the response of epidermal sheets
after reattachment to the dermis (Figure 6a and b). Reattach-
ment of the epidermis to the dermis restored the capacity of
the epidermis to respond to BRAF inhibition and demon-
strates the dermis directly or indirectly provides cues
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Figure 4. Rescue of spinous and granular keratinocyte expression by pharmacologic inhibition of BRAF or MEK. Wild type and K14-cre; BrafV600E explants were
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necessary for specification of spinous and granular kerati-
nocyte identity.
DISCUSSION
Epidermal differentiation is thought to occur in a linear
manner during the formation of the stratified layers in the
skin. Progressive pattern of differentiation is seen in other
tissues, including early embryogenesis, hematopoiesis, neuro-
genesis, T- and B-cell selection, and elsewhere (Morrison
et al., 1997; Lanzavecchia and Sallusto, 2002). On the basis of
RNA expression profiling of the K14-cre; BrafV600E mice, we
show that skin development may be less restrictive compared
to other models of progressive differentiation (Caplan and
Ordahl, 1978; MacLean, 1987).
Evidence from previous studies suggests that the intermedi-
ate stages of epidermal differentiation can have alternative
identities. During embryogenesis, a transient population of
K10pos suprabasal keratinocytes, known as the stratum inter-
medium, continues to display proliferative potential (Sengel,
1976; Koster and Roop, 2007). In addition, changes in
keratinocyte identity and potential have been noted after
engraftment (Mannik et al., 2010). Further evidence of
alternative keratinocyte identities has also been observed in
the postnatal tail epidermis, where alternating patterns of K10
expression are observed in suprabasal scale and interscale
keratinocytes (Gomez et al., 2013). These examples and the
results of the K14-cre; BrafV600E mouse indicate that spinous
and granular keratinocyte differentiation may not be a
required step in epidermal differentiation.
The loss of a cell type or stage presents a common dilemma
in stem cell biology, where loss of lineage markers may signify
either a change in cell identity or a more limited change––e.g.,
downregulation of specific markers (Spivakov and Fisher,
2007). To determine whether a ‘‘silent’’ spinous and
granular keratinocyte cell identity persist in BRAF-activated
keratinocytes, we tested the cell autonomy of the BRAF/MEK
inhibitor response. In both assays, isolated keratinocytes and
epidermal sheets, BRAF and MEK inhibition failed to rescue
spinous and granular keratinocyte gene expression. The results
of these studies suggest that these particular cell types require
additional signals to re-activate spinous and granular
identities. Whether these cells adopt an alternative identity
in the K14-cre; BrafV600E mouse remains to be determined.
The K14-cre; BrafV600E mouse model exhibits a model for
epidermal hyperproliferation in addition to the absence of
intermediate layers. The overexpression of RAF1-estrogen
receptor fusion protein similarly displays basal hyperprolifera-
tion and impairs epidermal differentiation (Tarutani et al.,
2003). Hyperproliferation of the epidermis, however, is not
always linked to a block in differentiation. For example, both
overexpression of Transforming growth factor-alpha or
conditional activation of KrasG12D lead to hyperproliferation
but do not block epidermal differentiation (Vassar and Fuchs,
1991; Mukhopadhyay et al., 2011). Thus, the inhibitory effects
of RAS/MAPK signaling may be more specific to BRAF or RAF
activation. Mouse models of activated Hras, Kras, Raf1, and
Braf have previously been reported. These mice surprisingly
exhibit major differences in skin phenotypes and even lack of
skin phenotypes (Tarutani et al., 2003; Schuhmacher et al.,
2008; Chen et al., 2009; Mukhopadhyay et al., 2011;
Urosevic et al., 2011). A previously reported BrafV600E/
BrafV600E germline mutation in mouse does not lead to
major epidermal differentiation defects (Urosevic et al.,
2011). The knock-in targeting strategy used to generate the
conditional BrafV600E allele used in our study differs from the
germline BrafV600E/BrafV600E mouse model, which expresses
the mutant allele at different levels (80% of wild-type levels in
the conditional BrafV600E model vs. B30% in the germline
BrafV600E/BrafV600E) (Supplementary Figure S6 online). These
differences in expression levels of BrafV600E likely account for
differences in skin phenotypes. Neither mouse model
(BrafV600E allele) completely recapitulates alleles found in
human cardiofaciocutaneous syndrome; however, species
differences such as the relative resistance of rodent models
to RAS (Kakumoto et al., 2006; Muto et al., 2006) further
complicate these comparisons.
Our findings may have medical relevance to the manipula-
tion of the BRAF/MEK pathway in the treatment of several
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Figure 5. Fate of pulse-labeled basal keratinocytes in wild-type and BrafV600E
explants. To determine the origin of spinous and granular layer revertants in
wild-type and BrafV600E explants, proliferating basal keratinocytes were labeled
in utero with BrdU, and after embryo harvest and explant culture for 24 hours
in the presence of vehicle or PLX4720, BrdU was localized. (a) Double staining
for K10 and pulse-chase BrdU demonstrates the labeling at time 0 hours and
retention in post-mitotic cells 24 hours after vehicle vs. PLX4720 treatment.
(b) Double staining for loricrin and pulse-chase BrdU demonstrates lack of
BrdU-labeled cells in loricrin-positive cells. In all panels, dotted lines indicate
epidermal junction with the dermis. Scale bars=20mm.
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epidermal disorders. In the human skin, defects in intermedi-
ate stages of epidermal differentiation can be seen. In
psoriasis, loss or reduction in granular keratinocyte differentia-
tion has been observed (Chowaniec et al., 1981). Similarly, in
the wound response, spinous and granular keratinocyte
markers are downregulated (Patel et al., 2006; Ortonne
et al., 1981). In both settings, increased RAS/MAPK signaling
has been reported (Sosnowski et al., 1993; Lin et al., 1999).
Our findings support the model that RAS/MAPK signaling may
be responsible for some aspects of these epidermal changes;
however, further studies are needed to determine how human
skin conditions respond to BRAF/MEK inhibition.
MATERIALS AND METHODS
Animal studies
Conditional BrafV600E (Dankort et al., 2007) and K14-cre mice
(Vasioukhin et al., 1999) were maintained on a mixed genetic
background, including outcrosses to Swiss Black. Intercrosses were
performed using K14-cre males and floxed hemizygous BrafV600E
females. Embryonic age, beginning at noon E0.5, was based on the
day of post-coital plug detection. Animals were genotyped using
primers in the study by Dankort et al., (2007). Wild-type littermates
were used as controls. Expression of Braf in wild-type and BrafV600E
mice is shown in Supplementary Figure S4 online. All experiments
were performed and approved according to the institutional
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Figure 6. Reversion of BrafV600E explants is not cell autonomous, requiring a dermal signal. (a) Schematic of preparation of explants, epidermis-only vs. epidermis
with the dermis reattached. (b) Spinous K10 expression in epidermis-only explants vs. epidermis reattached to the dermis from wild type and K14-cre; BrafV600E
E17.5 embryos treated with BRAF inhibitor, PLX4720. Right panels demonstrate single channel of K10 expression. (c) Granular LOR expression was examined in
wild-type and BrafV600E epidermis, demonstrating the requirement for dermal reattachment for proper reactivation of LOR protein expression. Right panels
demonstrate single channel of LOR expression. Scale bar=20mm.
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guidelines established by the University of California, San Diego,
Institutional Animal Care and Use Committee.
Assays for barrier function
Embryos were collected from E15.5 to E17.5. Dye exclusion assays
were performed as essentially as described (Hardman et al., 1998).
Briefly, embryos were transferred through a methanol gradient and
stained in 1% toluidine blue for 10 minutes and destained. To isolate
cornified sheets, frozen embryonic skin was thawed and treated
with Dispase II (Roche, Rotkreuz, Switzerland) for 1 hour at 37C,
trypsinized, washed, and isolated. Dark field images of cornified
sheets were observed with Olympus MVX10 stereomicroscope.
Tissue collection, storage, and RNA extraction
Tissue for immunostaining and histology was fixed in 4% paraformal-
dehyde and stored at 4 1C or flash frozen in OCT. Isolated epidermal
sheet was obtained from embryonic skins incubated with Dispase II
(Roche) and separated from the underlying dermis. RNA was extracted
from epidermal sheets that were placed in Trizol reagent (Invitrogen,
Carlsbad, CA) and disrupted with 1 mm zirconia beads (BioSpec
Products, Bartlesville, OK). Prior to use, RNA was treated with RNase-
free DNase and further concentrated using a RNA Clean & Concen-
trator kit (Zymo Research, Irvine, CA).
Histology, immunofluorescence, in situ hybridization
For immunofluorescent staining, the primary and secondary antibodies
used in this study are described in Supplementary Methods online. In
situ hybridizations were performed essentially as described (Etchevers
et al., 2001). Riboprobes were generated using T7 or SP6-modified
oligos (Supplementary Table S1 online) and amplified by PCR.
RNA analysis by real-time PCR and high-throughput sequencing
Primer sequences are detailed in Supplementary Table S3 online
using Primer3 (Rozen and Skaletsky, 2000), and real-time qPCR
performed with Maxima First Strand cDNA Synthesis and SYBR
Green/ROX qPCR Kits (Thermo Fermentas, San Francisco, CA) in
triplicate on a Lightcycler 480 (Roche). A comparative CT method
was used for analysis using Gapdh or Beta-actin for mouse mRNAs
(Schmittgen and Livak, 2008).
For RNA sequencing, total RNA was pooled from four wild-type
and mutant E17.5 epidermal sheets. NuGEN Ovation RNASeq v1 was
used to generate cDNA, fragment, end repair, and polyA-tail follow-
ing the TruSeq (Illumina, San Diego, CA) protocol. Raw data were
processed using BOWTIE, FASTX-Toolkit and aligned to the mouse
genome (mm9) (Trapnell et al., 2009). For assembly and
quantification, Cufflinks (Trapnell et al., 2012) were used and
differentially expressed genes identified by Cufflinks were expressed
as log2-fold changes of mean FPKM of mutant and wild-type RNAs.
Benjamini-Hochberg-corrected q-values were reported in volcano
plots. RNA-seq data will be accessioned at NCBI SRA Archive,
SUB373241.
Explant assay and drug treatment
Explant cultures were performed as previously described with small
modifications (Halprin et al., 1979). In brief, embryonic skin was
isolated, cut into 4 2 mm strips, placed on a gelatin-coated 10mm
Isopore membrane filter (Millipore, Temecula, CA), and floated
over Dulbecco’s Modified Eagle’s medium, 10% fetal calf serum
(Invitrogen), with antibiotics at 37 1C for 0–24 hours in 7% CO2.
Explants were treated with vehicle, U0126 (Promega, Madison, WI),
or PLX4720 (EMD Chemicals, Temecula, CA) solubilized in dimethyl
sulfoxide (o0.2% final). RNA was isolated from samples as described
above, except that the whole skin was used, and immunostained
sections were obtained from fixed explant tissue. For pulse-chase
studies, 50mg BrdU g 1 was injected intraperitoneally in pregnant
mice 2 hours prior to isolation of embryos. Explants were fixed for
1 hour, blocked in OCT, and 8mm sections were cut, rehydrated with
decreasing concentrations of ethanol, denatured in 4N HCl, neutra-
lized, trypsinized, and inactivated. The tissues were stained with anti-
BrdU (1:200; Sigma-Aldrich, St Louis, MO) with secondary detection
using the MOM kit (Vector Laboratories, Burlingame, CA) and
Strepavidin-Alexa 488 (Life Technologies, Carlsbad, CA).
Epidermal sheets prepared from Dispase II (Roche)–treated embryo-
nic skin. For dissociation, epidermal sheets were further treated
with Accutase (Chemicon, Temecula, CA/Millipore), inactivated,
and placed in the same media and growth conditions as described
above. Viability of epidermal sheets and keratinocytes was validated
by the presence of active transcription assessed at the end of 24 hour
culture with 2 hour actinomycin treatment.
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